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Precise redox-sensitive cleavage sites for improved
bioactivity of siRNA lipopolyplexes†
Philipp Michael Klein,‡a Sören Reinhard,‡a Dian-Jang Lee,a,b Katharina Müller,a
Daniela Ponader,c Laura Hartmannd and Ernst Wagner*a,b
Lipo-oligomers have been proven as potent siRNA carriers based on stable electrostatic and hydrophobic
complex formation and endosomal membrane destabilization. Although high stability of siRNA polyplexes
is desirable in the extracellular space and cellular uptake, intracellular disassembly is important for the
cytosolic release of siRNA and RNA-induced silencing complex formation. To improve the release, bio-
reducible sequence-defined lipo-oligomers were synthesized by solid-phase assisted synthesis using the
disulfide building block Fmoc-succinoyl-cystamine for precise positioning of a disulfide unit between a
lipophilic diacyl (bis-myristyl, bis-stearyl or bis-cholestanyl) domain and an ionizable oligocationic siRNA
binding unit. Reducible siRNA polyplexes show higher gene silencing efficacy and lower cytotoxicity than
their stable analogs, consistent with glutathione-triggered siRNA release and reduced lytic activity.
Introduction
RNA interference (RNAi) initiated by cytosolic delivery of syn-
thetic small interfering RNA (siRNA) provides innovative thera-
peutic opportunities for the regulation of disease-associated
genes.1,2 A dynamic and bioresponsive design of the delivery
system is essential to overcome various extracellular and intra-
cellular hurdles.3–12 Driven by electrostatic interaction with
negatively charged nucleic acids and intermolecular hydro-
phobic association, cationic lipids or lipo-oligomers assemble
into lipopolyplexes. This type of carrier stands out due to high
siRNA complex stability and transfection efficiency.13–15
Establishment of clear structure–activity relationships for
further optimization depends on availability of polymeric car-
riers with precise chemical structure.16,17 Solid-phase sup-
ported synthesis (SPS) is one approach for accurate assembly in
a defined way.18–25 Combining natural with artificial amino
acids and other synthetic building blocks, oligomers with
specific topologies and different functional elements can be
designed; our previous work demonstrated the beneficial effect
of hydrophobic elements and disulfide-forming cysteines on
siRNA polyplex stabilization.26–28 Maximum stabilization,
however, was not advantageous for gene silencing; the incor-
poration of disulfide bonds should facilitate disassembly of
polyplexes in the intracellular reductive milieu caused by
increased cytosolic glutathione (GSH) concentrations.29–32
Cysteine-based disulfide formation during polyplex formation
by air oxygen is a poorly controllable, incomplete process.21,24
Alternatively, integration of bioreducible bonds into carriers
can be achieved before nanoparticle formation by polymeriz-
ation reactions with disulfide-bearing compounds.30–32 The
positioning of the bioreducible element can to some extend be
controlled via sequential assembly of the carrier. Disulfide
bonds can be more accurately integrated during SPS of poly-
mers, as already demonstrated by Hartmann et al.33 Cleavable
cationic domains as well as disassembly of stabilizing domains
have been demonstrated to improve delivery systems.29
In the current work, we designed novel bioreducible cat-
ionic lipo-oligomers. By precisely positioning the disulfide
bond between the fatty acid and polycationic domain (and not
into the polycationic domain) via a Fmoc-succinoyl-cystamine
building block, we intended to obtain a most drastic molecular
change upon bioreduction. The amphiphilic, detergent-like
character, which is considered favorable for endosomolysis but
might also be associated with cytotoxicity, should be abolished
upon entry into the reductive cytosol by the split into separate
pure lipidic and cationic fragments; the latter fragments have
insufficient ability to bind siRNA.
In this study, we evaluate three lipo-oligomer topologies
(T-shape, i-shape and U-shape) and different representatives of
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fatty acids as variables, which previously were found26 to affect
polyplex characteristics such as siRNA binding and lytic poten-
tial of oligomers, gene silencing efficacy and toxicity of poly-
plexes. Compared with their nonreducible lipo-oligomer
analogs, the favorable polyplex characteristics should remain
indifferent until intracellular release into the cytosol, where




Protected Fmoc-α-amino acids, 2-chlorotrityl chloride resin,
N,N-dimethylformamide (DMF), N,N-diisopropylethylamine
(DIPEA) and trifluoroacetic acid (TFA) were purchased from
Iris Biotech (Marktredewitz, Germany). Triisopropylsilane
(TIS), 1-hydroxybenzotriazole (HOBt), glutathione (GSH) and
Triton X-100 were purchased from Sigma-Aldrich (Munich,
Germany). (Benzotriazol-1-yloxy)tripyrrolidinophosphonium
hexafluorophosphate (PyBOP) and microreactors were
obtained from MultiSynTech (Witten, Germany). Cell culture
media, antibiotics and fetal calf serum (FCS) were purchased
from Invitrogen (Karlsruhe, Germany), HEPES from Biomol
GmbH (Hamburg, Germany), glucose from Merck (Darmstadt,
Germany), agarose NEEO Ultra-Qualität from Carl Roth GmbH
(Karlsruhe, Germany) and GelRed™ from VWR (Darmstadt,
Germany). Citrate-buffered human blood was provided by
Klinikum der Universität München (Munich, Germany). Cell
culture 5 × lysis buffer and D-luciferin sodium salt
were obtained from Promega (Mannheim, Germany). Ready-to-
use siRNA duplexes were obtained from Axolabs
GmbH (Kulmbach, Germany): eGFP-targeted siRNA (siGFP)
(sense: 5′-AuAucAuGGccGAcAAGcAdTsdT-3′; antisense:
5′-UGCUUGUCGGCcAUGAuAUdTsdT-3′; small letters: 2′methoxy;
s: phosphorothioate) for silencing of eGFPLuc; control siRNA
(siCtrl) (sense: 5′-AuGuAuuGGccuGuAuuAGdTsdT-3′; anti-
sense: 5′-CuAAuAcAGGCcAAuAcAUdTsdT-3′). All solvents and
other reagents were purchased from Sigma-Aldrich (Munich,
Germany), Iris Biotech (Marktredwitz, Germany), Merck
(Darmstadt, Germany) or AppliChem (Darmstadt, Germany).
Synthesis of disulfide-linker building block (ssbb)
15.0 g of cystamine dihydrochloride (66.6 mmol, 1 eq.) were
suspended in 150 mL of THF with 23.2 ml of DIPEA
(133.2 mmol, 2 eq.) and cooled down to −80 °C. 18.0 g
(53.3 mmol, 0.8 eq.) of Fmoc-OSu were dissolved in 200 mL of
THF and added dropwise over the course of 3 h. The reaction
was stirred for additional 1 h at −80 °C and then for 1 h at RT.
DIPEA (23.2 mL, 133.2 mmol, 2 eq.) was added and the reac-
tion mixture was cooled to 0 °C. Succinic anhydride (12.0 g,
119.9 mmol, 1.8 eq.) was dissolved in 150 mL of THF. This
solution was added dropwise to the reaction mixture at 0 °C
and stirred over-night. The reaction mixture was concentrated
to approximately 200 mL, mixed with 200 mL of DCM and was
washed 5× with 0.1 M sodium citrate buffer (pH 5.2). The
organic phase was dried over sodium bicarbonate, concen-
trated and purified by dry column vacuum chromatography
(DCVC) using a n-heptane/EtOAc gradient (starting from 1 : 1)
to elute Fmoc-byproducts, followed by a EtOAc/MeOH gradient
to isolate the product. The solvent was removed under reduced
pressure to give 6.2 g of a white solid (13.1 mmol, 24.5%).
Oligomer synthesis
Oligomers were synthesized using a 2-chlorotrityl resin pre-
loaded with the first C-terminal amino acid of the respective
topology (see ESI†) as solid support. Artificial Fmoc-oligo-
amino acid Fmoc-Stp(Boc3)-OH was synthesized as described
before.23,34 Oligomers of artificial oligoamino acids were syn-
thesized manually under standard Fmoc solid phase peptide
synthesis conditions using syringe microreactors. Coupling
steps were carried out using 4 eq. Fmoc-amino acid, 4 eq.
HOBt, 4 eq. PyBOP and 8 eq. DIPEA in DCM–DMF 1 : 1 (10 mL
g−1 resin) for 90 min. In case of coupling Fmoc-succinoyl-cyst-
amine no HOBt was used and only DMF was used as solvent.
All couplings after Fmoc-succinoyl-cystamine were carried out
without HOBt. Fmoc deprotection was accomplished by
4 × 10 min with 20% piperidine in DMF (10 mL g−1 resin).
After each coupling and deprotection step, a washing pro-
cedure comprising 3 × 1 min DMF, 3 × 1 min DCM incubation
(10 mL g−1 resin) and a Kaiser test35 were performed. In case
of a positive result of the Kaiser test after coupling, the last
coupling step was repeated. In case of a negative result after
deprotection, the last deprotection step was redone.
Symmetrical branching points were introduced using Fmoc-
Lys(Fmoc)-OH, asymmetric branching in T-shape structures
was introduced using Fmoc-Lys(Dde)-OH. Dde-deprotection
was performed 30 times with a Syro Wave™ synthesizer
(Biotage, Uppsala, Sweden). Hydrazine–DMF solution 1 : 50
was added and vortexed for 2 min. The reaction solvent was
drained and fresh solution was added again. Afterwards the
resin was washed with 5 × 1 min DMF and 3 × 1 min DCM
(10 mL g−1 resin).
Finally, all oligomers were cleaved off the resin by incu-
bation with TFA–TIS–H2O 95 : 2.5 : 2.5 (10 mL g
−1 resin) for
90 min. The cleavage solution was concentrated by flushing
nitrogen and oligomers were precipitated in 40 mL of pre-
cooled MTBE–n-hexane 1 : 1. All oligomers were purified by
size exclusion chromatography using an Äkta purifier system
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden), a Sephadex
G-10 column and 10 mM hydrochloric acid solution–aceto-
nitrile 7 : 3 as solvent. All oligomers were lyophilized. Oligomer
sequences were validated by mass spectrometry and 1H-NMR.
siRNA polyplex formation
siRNA and oligomer at indicated nitrogen/phosphate (N/P)
ratios were diluted in separate tubes of equal volumes of
20 mM HEPES buffered 5% glucose pH 7.4 (HBG) each. If no
other description is provided, 500 ng siRNA were dissolved in
10 µL HBG. Only protonatable nitrogens were considered in
the N/P calculations. The polycation solution was added to the
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siRNA solution, mixed by rapid pipetting 5× and incubated for
40 min at RT.
siRNA binding assays
A 2.5% agarose gel was prepared by dissolving agarose in TBE
buffer (10.8 g of trizma base, 5.5 g of boric acid, 0.75 g of di-
sodium EDTA, and 1 L of water) and subsequent boiling. After
cooling down to about 50 °C, GelRed™ was added. Polyplexes
were formed using the stated N/P ratios, and placed into the
sample pockets after 4 µl of loading buffer (prepared from
6 mL of glycerine, 1.2 mL of 0.5 M EDTA, 2.8 mL of H2O,
0.02 g of bromophenol blue) was added. Electrophoresis was
performed at 100 V for 40 min.
siRNA polyplexes under reducing conditions
siRNA polyplexes were formed at N/P ratio 20. After polyplex
incubation, 5 µL of a GSH solution were added to 20 µL of the
polyplex solution. The GSH stock solution had a concentration
of 50 mM and pH was adjusted to 7.4. It was diluted to concen-
trations of 5 mM and 0.5 mM. Consequently, the resulting
solutions had the final concentrations 0.1 mM, 1 mM and
10 mM, respectively. HBG was used as negative control
(0 mM GSH). The solutions were incubated at 37 °C for
90 min. 5 µL loading buffer was added and a siRNA binding
assay was performed.
Erythrocyte leakage assay with or without previous reductive
treatment
Fresh, citrate-buffered human blood was washed with phos-
phate-buffered saline (PBS). The washed human erythrocyte
suspension was centrifuged and the pellet was diluted to
5 × 107 erythrocytes per mL with PBS (pH 7.4, 6.5 and 5.5). In
case of GSH treatment, oligomers were incubated in 10 mM
GSH in HEPES (pH adjusted to 7.4) at a concentration of 1 mg
mL−1 at 37 °C for 90 min. A volume of 75 μl of erythrocyte sus-
pension and 75 µL of oligomer solution (previously diluted
with PBS of the respective pH) were added to each well of a
V-bottom 96-well plate (NUNC, Denmark), resulting in a final
concentration of 7.5 µM oligomer per well. The plates were
incubated at 37 °C under constant shaking for 1 h. After cen-
trifugation, 100 µL of the supernatant was analyzed for hemo-
globin release at 405 nm wavelength using a microplate reader
(Spectrafluor Plus, Tecan Austria GmbH, Grödig, Austria).
Cell culture
Mouse neuroblastoma Neuro2A/eGFPLuc cells and human
prostate carcinoma DU-145/eGFPLuc cells, both stably trans-
fected with the eGFPLuc gene, were used for gene silencing
assays. Neuro2A/eGFPLuc cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM). DU-145/eGFPLuc cells
were grown in RPMI-1640 medium. Both culture media were
supplemented with 10% FCS, 100 U mL−1 penicillin and
100 μg mL−1 streptomycin. The cells were maintained in venti-
lated flasks in the incubators at 37 °C with 5% CO2 in a
humidified atmosphere. Cell lines were grown to 80–90% con-
fluency and harvested.
Reporter gene silencing assay
Gene silencing assays were performed using Neuro2A/eGFPLuc
or DU145/eGFPLuc cells. The siRNA against eGFP (siGFP) for
silencing the eGFPLuc gene or its control sequence (siCtrl)
was exploited. 5000 cells per well were seeded on 96-well
plates, and medium was replaced with 80 μL fresh growth
medium after 24 h. Polyplex solution (20 µl, prepared as
described above) at indicated N/P ratios was added to each
well and incubated for 48 h at 37 °C. After transfection,
medium was removed and cells were treated with 100 μL cell
lysis buffer. Luciferase activity in the cell lysate was measured
using a luciferase assay kit (Promega, Mannheim, Germany)
and a Centro LB 960 plate reader luminometer (Berthold
Technologies, Bad Wildbad, Germany). The experiments were
performed in triplicates, and the relative light units (RLU) were
presented as percentage of the luciferase gene expression
obtained with HBG-treated control cells.
Results and discussion
A building block applicable for standard Fmoc solid-phase
peptide synthesis requires a protected amino group and a free
carboxylic acid function. The synthesis of the disulfide build-
ing block (ssbb) was carried out starting from cystamine by
selective protection of one terminal amine with Fmoc in the
first step avoiding change of protecting groups as was pre-
viously presented.36 To achieve reaction selectivity towards
mono-functionalization, 0.8 eq. Fmoc-succinimide (Fmoc-OSu)
was added dropwise to a cooled solution (−80 C) of cystamine
dihydrochloride in THF with DIPEA as a base. The carboxylic
acid function was introduced in the second step by addition of
1.8 eq. succinic anhydride (Succ anhydride) solved in THF
with DIPEA (Fig. 1A). The ssbb structure was purified via
Fig. 1 (A) Synthesis of the disulfide building block Fmoc-succinoyl-
cystamine (Fmoc-ssbb). (B) Gluthathione (GSH) triggered cleavage of
test structure (740) with a hydrophilic (Stp2) and a hydrophobic (L3) part
connected by ssbb. (C) Test structure monitored by HPLC (280 nm
wavelength) after incubation for 90 min at 37 °C in 0.1 mM GSH- (top)
and 10 mM GSH- (bottom) containing HEPES buffer pH 7.4.
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column chromatography and the identity confirmed by
1H-NMR. A test structure (740) was synthesized on solid phase
to prove the applicability for SPS. Here the ssbb connects a
lipophilic peptide sequence containing three leucines (L3) to a
hydrophilic sequence with two succinyl-tetraethylene penta-
mine (Stp) units (Fig. 1B). Tryptophane (W) was incorporated
into both parts to facilitate photometric analysis. The product
structure was confirmed by mass spectrometry and 1H-NMR.
The product was incubated with increasing concentrations of
the physiological antioxidant glutathione (GSH) at 37 °C to
simulate the behavior of the ssbb at different extra- and intra-
cellular milieus. A GSH concentration of 0.1 mM mimics the
barely reducing extracellular environment. As expected, the test
oligomer mostly retained its structural integrity. Increasing the
GSH concentration to 10 mM resembling the cytosolic reducing
conditions resulted in cleavage of the test structure without
detectable fractions of intact oligomer (Fig. 1C).
Next, the ssbb unit was applied in SPS of lipo-oligomers
supposed to form siRNA polyplexes that are stable in the extra-
cellular and labile in the intracellular environment. Lipo-oligo-
mers with three different topologies, T-shape, i-shape, and
U-shape, were synthesized (Fig. 2 top and S1†). As shown in
our previous work, topologies as well as specific moieties of
structures may influence the biophysical and biological pro-
perties of the resulting polyplexes.17,24,26,27 For bioreducible
crosslinking between oligocations, previous oligomers were
designed with cysteines terminating the cationic back-
bone.24,26,27 Differently, in the current work the ssbb unit was
positioned between the ionizable oligocationic part of the
molecule and a bis (fatty acid) unit. Thus, upon reductive clea-
vage maximum destabilization of the polyplex on the one
hand, and abolition of the membrane-active amphiphilic char-
acter on the other hand, should be achieved. The oligocation
part contains several Stp units as artificial oligoamino acids
for nucleic acid binding and endosomal protonation,23 and
lysines (K) as branching units. Additionally, the cationic part
was equipped with tyrosine trimers (Y3)
27 for further hydro-
phobic stabilization of the T-shape oligomers (Fig. 2), and with
histidine blocks (H6) for increased endosomal buffering of the
i-shape oligomers. The saturated C14 short chain myristic acid
(MyrA), the stearic acid (SteA) with the longer C18 chain, and
the bulky cholanic acid (CholA) were incorporated as fatty
acids for hydrophobic polyplex stabilization. For all oligomers,
the corresponding non-reducible control structures lacking
ssbb were synthesized. The ssbb was incorporated into various
different structures to proof the concept independently of
shape and other functional domains and to put this work into
a broader context. The structures were analyzed with mass
spectrometry and 1H-NMR (Fig. 3A and ESI†). To exclude that
lipo-oligomers contain significant amounts of reduced frag-
ments, Ellman’s assay was performed to detect free thiols
(Table S1†). Lack of free thiols (<3%) indicate high integrity of
the ssbb linkage.
Polyplexes were formed by mixing the cationic oligomers
with siRNA, followed by 40 minutes incubation and biophysi-
cal characterization (Fig. 3 for stable and reducible CholA
T-shapes 991 and 992; see ESI† for other structures). The
siRNA binding ability of oligomers was determined by measur-
ing the electrophoretic mobility of siRNA in a 2.5% agarose
gel. Different N/P values depict the ratio of protonatable
amines (N) of the oligomer to phosphates (P) of the siRNA.
This does not present charge ratios, as only a fraction of the
protonatable amines are protonated at physiological pH. All
T-shape, i-shape and U-shape structures showed sufficient
binding at N/P ≥ 12 (Fig. 3C, S2 and S3†). Neither stable nor
reducible polyplexes released free siRNA when exposed to 90%
full serum at 37 °C for two hours, indicating a high extracellu-
lar stability (Fig. S4†). In contrast, treatment of polyplexes with
the physiological reducing agent GSH at 37 °C resulted in a
dose-dependent loss of siRNA binding efficacy for the reduci-
ble but not the stable oligomers (Fig. 3C, S5 and S6†). Due to
the particular position of the ssbb unit, reductive cleavage
leads to the release of the lipid as the most important stabiliz-
ation motif, thus keeping only a weak binding ability of the
remaining cationic backbone.27 This destabilization of poly-
plexes is expected to provide better accessibility of siRNA at
intracellular GSH concentrations (∼10 mM).
Fig. 2 Sequence-defined oligomers with T-shape topology. Top:
Schematic overview of the structures with different modifications
(Y: tyrosine, K: lysine, G: glycine, Stp: succinoyl-tetraethylene-pentamine,
ssbb: succinoyl-cystamine, MyrA: myristic acid, SteA: stearic acid,
CholA: 5β-cholanic acid). The broken lines represent amide linkages. IDs
are unique database identification numbers. i-shape and U-shape struc-
tures are depicted in Fig. S1.† Bottom: Cellular uptake, acidic pH-trig-
gered endosomal escape, and GSH triggered cytosolic disassembly of
siRNA polyplexes.
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The particle sizes of siRNA lipopolyplexes were measured
by dynamic light scattering (DLS). All T-shape polyplexes
showed uniform sizes between 105–138 nm z-average (Fig. 3B
and Table S2†). The sizes of i-shape and U-shape polyplexes
showed higher polydispersity. All formulations revealed a
positive zeta potential of around 23–32 mV due to an excess of
cationic oligomer (Table S2†). T-shape oligomers were found
as well-suited for the evaluation of structure–activity relation-
ships, since they all formed polyplexes with reliable sizes and
low polydispersity.
Gene silencing experiments were performed in Neuro2A
neuroblastoma cells stably expressing an eGFP-Luciferase
fusion protein (Fig. 4). Silencing by siGFP (light bars) can be
quantified by a standard luciferase assay. In all cases, gene
silencing was more effective for the bioreducible T-shape oligo-
mers (Fig. 4B) as compared to their stable analogs (Fig. 4A).
A reduced luciferase expression in control experiments using
siCtrl (dark bars) is caused by unspecific cytotoxic effects and
not by a specific knockdown of the eGFPLuc gene. Thus, from
evaluating the luciferase levels of the siCtrl polyplexes, an
enhanced biocompatibility of the reducible structures (Fig. 4B)
can be concluded. Similar findings, an enhanced gene silen-
cing and especially the reduction of cytotoxicity, were also
made for bioreducible i-shape and U-shape lipo-oligomers
(Fig. S7†). For the best-performing T-shape structures with
MyrA and CholA, dose-dependent gene silencing experiments
were carried out. Based on the starting formulation of 37 pmol
siRNA (370 nM) with 1.44 nmol oligomer (N/P 12), the dose of
siRNA was reduced either at a constant N/P 12 (Fig. S8†) or a
constant dose of 1.44 nmol oligomer (Fig. S9†). In the latter
case, significant gene silencing was still observed for reducible
MyrA polyplexes at 1.2 pmol/12 nM siRNA. The beneficial
effects of reducible polyplexes are also confirmed in DU145/
eGFPLuc prostate cancer cells (Fig. S10†).
When focusing on the comparison of the three different
fatty acids, SteA and CholA lipo-oligomers (no or only moder-
ate silencing for the stable versions) strongly benefited from
Fig. 3 (A) Analytical characterization of stable oligomer 991 and bio-
reducible oligomer 992 by mass spectrometry. (B) Agarose gel shift
assays. Left: siRNA binding at different N/P ratios. Right: Lipopolyplexes
formed at N/P 20 and subsequent 90 min treatment at 37 °C with
different concentrations of GSH in HEPES buffer pH 7.4. (C) Biophysical
characterizations of lipopolyplexes formed with oligomers and siRNA at
N/P 12 by DLS.
Fig. 4 Gene silencing of T-shape oligomers in neuroblastoma cells.
Lipopolyplexes with 500 ng/37 pmol eGFP-targeted siRNA (siGFP)/well
respectively control siRNA (siCtrl) at N/P 6, 12 and 20 were tested for
eGFPLuc gene silencing in Neuro2A-eGFPLuc cells. (A) Lipopolyplexes
made of stable structures 1081, 989 and 991 (B) lipopolyplexes made of
bioreducible structures 1082, 990 and 992. The luciferase activity of
siRNA treated cells is presented related to buffer treated cells. HBG-
treated cells were set to 100%. Data are presented as mean value (±SD)
out of triplicates. Dose-dependent gene silencing transfections are
shown in Fig. S8 and S9.†
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the incorporation of the ssbb with regard to gene silencing. In
contrast, the stable MyrA lipo-oligomer displayed gene silen-
cing activity combined with significant cytotoxicity (Fig. 4A);
here the reducible ssbb unit eliminated the cytotoxicity
without reducing the gene silencing activity (Fig. 4B). The find-
ings for non-reducible lipo-oligomers are consistent with our
earlier observations,26 where SteA derivatives showed poor
gene silencing activity and MyrA derivatives exhibited not only
gene silencing activity but cytotoxicity. For non-reducible struc-
tures, the unsaturated C18 fatty acids oleic acid and linoleic
acid were the optimum lipid units with regard to transfection
efficacy and cell tolerability.24,26,27 Still, due to the higher
stability during synthesis and storage, in the current work
saturated fatty acids were the preferred option for integration
into solid phase synthesized lipo-oligomers. Nevertheless,
incorporation of the bioreducible linker into oleic acid con-
taining oligomers was also found to further enhance trans-
fection efficacy and cell tolerability (Fig. S11†).
The different fatty acids may influence the extent of hydro-
phobic stabilization of siRNA polyplexes, but do also strongly
affect the lytic properties of the lipo-oligomers, both in the
stable and reducible setting. At endosomal pH, the cationic
parts receive increased cationization, which in combination
with the hydrophobic domain facilitates endosomal mem-
brane destabilization and escape into the cytosol. An erythro-
cyte leakage assay compared the different fatty acid versions of
stable (Fig. 5A) and the ssbb containing reducible (Fig. 5B)
lipo-oligomers. MyrA structures displayed a far higher leakage
activity (highest at pH 5.5) than the SteA structures, whereas
oligomers with the bulky CholA did not display lytic effects.
This finding is in agreement with literature, showing that cat-
ionic dimyristyl lipids strongly promote membrane fusion
events. Deviations of hydrophobic volume and hydrophilic–
lipophilic ratio from an optimum hampered membrane inter-
actions.37 Treatment with GSH did not affect the stable
analogs but extinguished the lytic activity of the reducible lipo-
oligomers, consistent with their lower cytotoxicity. This obser-
vation can be attributed to the integration of the ssbb as a
linker between the cationic and the lipophilic part, as reduc-
tive cleavage results in an uncharged fatty acid structure and
an oligocationic part with significantly reduced amphiphilic
character. Both compounds alone were not able to lyse mem-
branes anymore.
Conclusions
We report novel lipo-oligomers as siRNA carriers with high
gene silencing efficacy, which combine extracellular polyplex
stability with siRNA release under cytosolic conditions, and a
high lytic activity under endosomal conditions with low cyto-
toxicity. These apparently contradictory functional character-
istics were programmed into the carriers by introduction of a
bioreducible disulfide bond between the cationic backbone
and the hydrophobic domain. Precise positioning was enabled
by a Fmoc-protected cystamine building block compatible with
solid phase assisted synthesis.
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